Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

Abstract The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we pres...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Naveen Pemmaraju, Claire Harrison, Vikas Gupta, Srdan Verstovsek, Bart Scott, Stephen T. Oh, Francesca Palandri, Haifa Kathrin Al‐Ali, Marta Sobas, Mary Frances McMullin, Ruben Mesa, Sarah Buckley, Karisse Roman‐Torres, Alessandro Vannucchi, Abdulraheem Yacoub
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-11-01
coleção:	eJHaem
Assuntos:	myelofibrosis myeloproliferative neoplasms pacritinib safety
Acesso em linha:	https://doi.org/10.1002/jha2.591
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!